false
0000925741
0000925741
2025-03-26
2025-03-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 26, 2025
| |
BIOCARDIA, INC.
|
|
| |
(Exact name of registrant as specified in its charter)
|
|
| |
Delaware
|
|
001-38999
|
|
23-2753988
|
|
| |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
| |
320 Soquel Way
Sunnyvale, California 94085
|
|
| |
(Address of principal executive offices and zip code)
|
|
Registrant’s telephone number, including area code: (650) 226-0120
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001
|
BCDA
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 26, 2025, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOCARDIA, INC.
|
|
| |
|
|
/s/ Peter Altman, Ph.D.
|
|
|
Peter Altman, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
| |
|
|
Date: March 26, 2025
|
|
Exhibit 99.1
BioCardia Reports 2024 Business Highlights and Financial Results
Sunnyvale, Calif. – March 26, 2025 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission.
The Company will host a corporate update conference call on Monday, March 31, 2025 at 4:30 PM ET following its presentation of results from the CardiAMP HF Trial at the Late-Breaking Clinical Trials symposium at the American College of Cardiology 2025 Scientific Sessions in Chicago (see dial-in information below).
Recent Business Highlights
CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01)
| |
●
|
In the fourth quarter of 2024, we had a consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) regarding next steps for registration of the CardiAMP Cell Therapy System in Japan for the treatment of heart failure of reduced ejection fraction based on the data from our CardiAMP HF Trial. PMDA invited our next consultation after the submission of our clinical data with two-year follow-up and indicated they are open to considering the results from this and our previous trials being sufficient evidence for registration. |
| |
●
|
Also in this quarter, the CardiAMP HF Trial had its last protocol specified follow-up visit. Since then, our team has completed close out visits, data monitoring with source data verification and data freeze of primary outcome measures. Data analysis is near completion and results are being prepared for presentation at the Late-Breaking Clinical Trials symposium at the American College of Cardiology Scientific Sessions scheduled for this coming Sunday, March 30, 2025.
|
| |
●
|
In the coming weeks, we will be finalizing the initial trial manuscript for publication, sharing the results with the FDA and Japan’s PMDA, and accelerating enrollment activities in the CardiAMP HF II Trial.
|
CardiAMP autologous cell therapy in chronic myocardial ischemic with refractory angina (BCDA-02)
| |
●
|
The last patient enrolled into the open-label roll-in cohort reached their primary six-month endpoint in February 2025. We are gathering results of this cohort at the six-month primary endpoint for publication and presentation. |
CardiALLO Cell Therapy in Ischemic Heart Failure (BCDA-03)
| |
●
|
Treatment of the low dose cohort of 20 million cells has been completed and to our knowledge there have been no treatment-emergent adverse events, arrhythmias, rejection, or allergic responses. Per protocol, formal Data Safety Monitoring Board review of these patients will take place in the second quarter of 2025.
|
Morph Access Innovations
| |
●
|
The first commercial Morph DNA steerable introducer devices in 45 cm and 70 cm length and 5 and 8 French configurations have been manufactured at our Sunnyvale facility and are now available. Physicians will be using these in our CardiAMP and CardiALLO clinical trials, in programs with our therapeutic partners, and in commercial clinical procedures.
|
“We look forward to sharing the CardiAMP HF data at the American College of Cardiology Scientific Sessions this week,” said BioCardia CEO Peter Altman, Ph.D. “This data readout has potential to significantly de-risk development of our minimally invasive autologous cell therapy product candidate for patients with ischemic heart failure and may serve as the primary evidence to support product registration for market release.”
2024 Financial Results:
| |
>
|
Net cash used in operations was approximately $8.0 million during the year ended 2024, compared to approximately $10.0 million in 2023, primarily due to reductions in research and development expense following completion of the CardiAMP HF Trial. The Company ended the year with cash and cash equivalents totaling $2.4 million.
|
| |
>
|
Revenues were approximately $58,000 in 2024, compared to approximately $477,000 in 2023, due primarily to the fulfillment of performance obligations for several business partners.
|
| |
>
|
Research and development expenses decreased to approximately $4.4 million in 2024, compared to approximately $7.7 million in 2023, primarily due to reduced clinical expenses following the completion of the CardiAMP HF Trial.
|
| |
>
|
Selling, general and administrative expenses decreased to approximately $3.7 million in 2024, compared to approximately $4.4 million in 2023, primarily due to realignment of personnel and cost reductions following completion of the CardiAMP HF Trial.
|
| |
>
|
Our net loss decreased to approximately $7.9 million in 2024, compared to approximately $11.6 million in 2023.
|
ANTICIPATED UPCOMING MILESTONES AND EVENTS:
| |
>
|
BCDA-01: CardiAMP Autologous Cell Therapy for Ischemic Heart Failure
|
| |
–
|
Late Breaking Presentation at ACC on March 30, 2025
|
| |
–
|
Japan PMDA Clinical Consultation request / submission
|
| |
–
|
FDA Meeting request / submission
|
| |
–
|
Enrollment in the CardiAMP Heart Failure II Trial
|
| |
>
|
BCDA-02: CardiAMP Autologous Cell Therapy in Chronic Myocardial ischemia
|
| |
–
|
Completed roll-in cohort data submitted for presentation / publication
|
| |
>
|
BCDA-03: CardiAllo Allogeneic Cell Therapy in Inflammatory Ischemic Heart Failure
|
| |
–
|
Data Safety Monitoring Board review of completed low dose cohort
|
| |
>
|
Helix Biotherapeutic Delivery Business
|
| |
–
|
Biotherapeutic delivery partnerships
|
| |
>
|
Morph Access Innovations Business
|
| |
–
|
Revenues and case reports
|
Conference call access:
Participants can register for the conference by navigating to https://dpregister.com/sreg/10198270/fed22b3a96. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730 and ask to be connected to the BioCardia call. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fyO2WNaO.
A webcast replay of the call will be available approximately one hour after the end of the call at the above links. To access the replay internationally, please use the link https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6730403.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLOTM allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its HelixTM biotherapeutic delivery and Morph® vascular navigation platforms. The CardiAMP Cell Therapy Trial for Heart Failure has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services. For more information visit: www.BioCardia.com.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment in our clinical trials, the availability of data from our clinical trials, filings and communications with the FDA and Japan’s Pharmaceutical and Medical Device Agency, product clearances, the efficacy and safety of our products and therapies, preliminary conclusions about new data, the achievement of any of the anticipated upcoming milestones, our positioning for growth or the market for our products and therapies, the expected benefits of our intellectual property, future prospects, regulatory timelines, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter into licensing and partnering arrangements and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent the development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
BioCardia, Inc.
Condensed Consolidated Statements of Operations
(Unaudited in thousands, except share and per share amounts)
| |
|
Year ended
December 31,
|
|
| |
|
2024
|
|
|
2023
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
Collaboration agreement revenue
|
|
|
58 |
|
|
|
477 |
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
4,387 |
|
|
|
7,726 |
|
|
Selling, general and administrative
|
|
|
3,672 |
|
|
|
4,395 |
|
|
Total costs and expenses
|
|
|
8,059 |
|
|
|
12,121 |
|
|
Operating loss
|
|
|
(8,001 |
) |
|
|
(11,644 |
) |
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
Total other income, net
|
|
|
55 |
|
|
|
73 |
|
|
Net loss
|
|
$ |
(7,946 |
) |
|
$ |
(11,571 |
) |
| |
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted
|
|
$ |
(2.90 |
) |
|
$ |
(8.19 |
) |
| |
|
|
|
|
|
|
|
|
|
Weighted-average shares used in computing net loss per share, basic and diluted
|
|
|
2,743,828 |
|
|
|
1,411,998 |
|
BioCardia, Inc.
Selected Balance Sheet Data
(amounts in thousands)
| |
|
December 31,
|
|
|
December 31,
|
|
| |
|
2024(1)
|
|
|
2023(1)
|
|
| |
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
2,371 |
|
|
$ |
1,103 |
|
|
Other current assets
|
|
|
251 |
|
|
|
358 |
|
|
Property, plant and equipment and other noncurrent assets
|
|
|
1,102 |
|
|
|
1,526 |
|
|
Total assets
|
|
$ |
3,724 |
|
|
$ |
2,987 |
|
|
Liabilities and Stockholders’ Equity (Deficit)
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
$ |
2,321 |
|
|
$ |
3,608 |
|
|
Operating lease liability - noncurrent
|
|
|
566 |
|
|
|
982 |
|
|
Total stockholders’ equity (deficit)
|
|
|
837 |
|
|
|
(1,603 |
) |
|
Total liabilities and stockholders’ equity (deficit)
|
|
$ |
3,724 |
|
|
$ |
2,987 |
|
(1) December 31, 2024 and 2023 amounts were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on March 26, 2025.
###
Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
v3.25.1
Document And Entity Information
|
Mar. 26, 2025 |
| Document Information [Line Items] |
|
| Entity, Registrant Name |
BIOCARDIA, INC.
|
| Document, Type |
8-K
|
| Document, Period End Date |
Mar. 26, 2025
|
| Entity, Incorporation, State or Country Code |
DE
|
| Entity, File Number |
001-38999
|
| Entity, Tax Identification Number |
23-2753988
|
| Entity, Address, Address Line One |
320 Soquel Way
|
| Entity, Address, City or Town |
Sunnyvale
|
| Entity, Address, State or Province |
CA
|
| Entity, Address, Postal Zip Code |
94085
|
| City Area Code |
650
|
| Local Phone Number |
226-0120
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, par value $0.001
|
| Trading Symbol |
BCDA
|
| Security Exchange Name |
NASDAQ
|
| Entity, Emerging Growth Company |
false
|
| Amendment Flag |
false
|
| Entity, Central Index Key |
0000925741
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Grafico Azioni BioCardia (NASDAQ:BCDA)
Storico
Da Mar 2025 a Apr 2025
Grafico Azioni BioCardia (NASDAQ:BCDA)
Storico
Da Apr 2024 a Apr 2025
